Rat Models for CMT2A Axonal Neuropathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The lack of an animal model has hindered the investigation of how dominant MFN2 mutations cause peripheral neuropathy in Charcot-Marie-Tooth disease type 2A (CMT2A), making it difficult to assess pathogenesis and develop effective treatments.
Innovation Solution
Development of genetically authentic rat models harboring the R364W and H361Y mutations, which cause severe, early-onset axonal neuropathy, allowing for the creation of a robust neuropathy model that mimics the progression of CMT2A in humans, with histological and behavioral analyses demonstrating length-dependent axonal loss and gait abnormalities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If no animal model is developed, then research on CMT2A pathogenesis cannot proceed, but developing an animal model requires significant time and resources
Solution Approach 1:
The patent creates a rat model that copies the human CMT2A genetic mutation (MFN2 R364W) to reproduce the disease phenotype. By introducing the specific human mutation into the rat genome, the model replicates the axonal neuropathy characteristics of CMT2A, enabling research without requiring extensive de novo model development
Solution Approach 2:
The patent modifies the genetic parameter of the rat model by introducing the MFN2 R364W mutation. This parameter change transforms a healthy rat into a model that exhibits CMT2A pathology, providing a reliable system for studying disease mechanisms while avoiding the need to develop multiple different model systems
2Reliability
If a robust neuropathy model is created, then pathogenesis investigation is enabled, but the model complexity increases
Solution Approach 1:
The patent introduces the MFN2 mutation specifically in the rat model to create localized pathological changes in peripheral nerves. The mutation produces axonal neuropathy with specific characteristics (length-dependent axonal loss) while leaving other systems relatively unaffected, providing a focused model that is robust for neuropathy research without excessive overall complexity
Solution Approach 2:
The patent creates a progressive neuropathy model where axonal loss develops over time in a length-dependent manner. This dynamic progression mirrors human CMT2A, allowing researchers to study disease evolution at different stages without requiring multiple static models of varying complexity
3Manufacturing precision
If genetic mutation is introduced to create CMT2A model, then disease specificity is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent copies the exact human CMT2A mutation (MFN2 R364W) into the rat genome. This copying approach ensures genetic accuracy and disease specificity while using established gene targeting methods that reduce the difficulty of creating precise genetic modifications compared to developing entirely new models
Data Source
AI summary
The present invention relates to the engineering an animal model, preferably mammalian models, more preferably a rat model representing Charcot-Marie-Tooth disease 2A (CMT2A) harboring the p.Arg364Trp or p.His361Tyr Mfn2 mutation, whose human counterpart results in a severe, early-onset axonal neuropathy. A model having the p.Arg364Trp Mfn2 mutation is based on a mutation made using zinc finger endonuclease technology in fertilized rat eggs. Cohorts of mutants and wild type littermates were characterized behaviorally and shown to develop multiple motor deficits that worsened over time. Separate cohorts of mutant and wild type rats sacrificed at 7, 40, and 48 weeks and analyzed by light microscopy showed a reduced density of myelinated axons and active axonal degeneration in distal but not proximal nerves, as well as axonal degeneration in the fasciculus gracilis of the cervical spinal cord at 40 and 48 weeks. These findings were not present in the 7-week-old cohort of Mfn2 mutants, or in wild type rats at 7 or 40 weeks. A model having the p.His361Tyr Mfn2 mutation is based on a mutation made using CRISPR/Cas9 gene editing technology. This mutation showed abnormalities in gait dynamics at 8 weeks and a lengthening of the gait cycle at 16 weeks. A genetically authentic animal model for CMT2A developing a progressive axonal neuropathy is a valuable tool for examining the pathogenesis and treatment of CMT2A.